Skip to content

Cumberland Pharmaceuticals CPIX Share Repurchase Program, Remaining Authorized, Amount

Share Repurchase Program, Remaining Authorized, Amount at other companies

Baxter International logo
Baxter InternationalBAX

Other financials

Income statement

See full
Revenue$9.1M-22.0%
Gross profit$7.2M-30.0%
Operating income-$3.1M-342%
Net income-$3.3M-362%
EPS (diluted)-$0.22-375%

Balance sheet

See full
Cash & equivalents$11.0M-27.1%
Total debt$4.8M-7.1%
Total equity$21.6M-24.5%
Total assets$71.0M+1.5%

Cash flow

See full
Operating cash flow$387.0K-90.1%
CapEx--100%
Free cash flow$387.0K-89.9%

Valuation

See full
Market cap$97.09M+138%
Enterprise value$90.91M+207%
P/S2.3×+1.3×

Profitability

See full
Gross margin82.9%-1.4pp
Operating margin-17.2%-125pp
Net margin-17.6%-103pp
FCF margin3.3%

Returns & leverage

See full
Return on equity-29.4%-86.3pp
Debt / equity0.2×0.0×
Current ratio-0.3×

Where this comes from

Reported directly by Cumberland Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1.

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's share repurchase program, remaining authorized, amount.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cumberland Pharmaceuticals's share repurchase program, remaining authorized, amount?
Cumberland Pharmaceuticals (CPIX) reported share repurchase program, remaining authorized, amount of $2.1M in Q1 2026.
How has Cumberland Pharmaceuticals's share repurchase program, remaining authorized, amount changed year-over-year?
Cumberland Pharmaceuticals's share repurchase program, remaining authorized, amount decreased by 4.5% year-over-year, from $2.2M to $2.1M.